
Dr Lisa Rojkjaer, head of clinical development, MorphoSys
pharmafile | October 15, 2009 | Appointment | Research and Development |Â Â appointment, morphosys, research and developmentÂ
MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development.
Dr Rojkjaer joins MorphoSys from Novartis where she most recently held the position of head of medical affairs – hematology, Europe.
Before that she was global clinical programme head for Exjade, where she was responsible for all clinical activities in Europe for Novartis’ haematology portfolio including Gleevec and Exjade.
Prior to Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, USA as the director of global medical affairs biopharmaceuticals and later director, clinical development haematology.
During her time with Novo Nordisk she established a global medical affairs group for biopharmaceuticals and headed the clinical development of the US haematology portfolio amongst other accomplishments.
Dr Rojkjaer is a board certified haematologist and received her medical degree from the University of Toronto, where she also did her residency in internal medicine and fellowship in haematology.
She has held academic and hospital appointments in the US, Canada and Europe.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






